Gammagard Liquid and rHuPH20 in PID
Information source: Baxter Healthcare Corporation
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Primary Immunodeficiency Diseases (PID)
Intervention: Recombinant human hyaluronidase + immune globulin intravenous (Biological); Recombinant human hyaluronidase + immune globulin intravenous (Biological)
Phase: Phase 3
Status: Completed
Sponsored by: Baxter Healthcare Corporation Official(s) and/or principal investigator(s):
Baxter BioScience Investigator, MD, Study Director, Affiliation: Baxter Healthcare Corporation
Summary
The purpose of the study is to develop a subcutaneous treatment option for subjects with PID
that allows an administration of Immune Globulin Intravenous (Human), 10% at the same
frequency as IV administration.
Clinical Details
Official title: Efficacy, Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human), 10% (GAMMAGARD LIQUID/KIOVIG) Administered Intravenously or Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Subjects With Primary Immunodeficiency Diseases
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: The primary endpoint is the validated acute serious bacterial infection rate, defined as the mean number of validated acute serious bacterial infections per subject per year in the intent-to-treat population.
Eligibility
Minimum age: 2 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Subject is 2 years or older at the time of screening
- Written informed consent obtained from either the subject or the subject's legally
acceptable representative prior to any study-related procedures and study product
administration
- Subject has been diagnosed with a PID disorder requiring antibody replacement as
defined by WHO criteria
- Subject has completed or is about to complete Baxter Clinical Study Protocol No.
160601 or has been receiving a regular IGIV-treatment at mean intervals of 21 ± 3
days or 28 ± 3 days, or SC at mean intervals of 5 to 16 days, over a period of at
least 3 months prior to enrollment at a minimum dose of 300 mg/kg BW/4 weeks
- Subject has a serum trough level of IgG > 4. 5 g/L at the last documented
determination
- If female of childbearing potential, subject presents with a negative urine pregnancy
test and agrees to employ adequate birth control measures for the duration of the
study
- Subject is willing and able to comply with the requirements of the protocol
Exclusion Criteria:
- Subject is positive at enrollment or screening for one or more of the following:
Hepatitis B surface antigen (HbsAg), polymerase chain reaction (PCR) for Hepatitis C
Virus (HCV), PCR for Human immunodeficiency virus (HIV) Type 1/2
- Subject has levels of alanine aminotransferase (ALT) or aspartate amino transferase
(AST) > 2. 5 times the upper limit of normal for the testing laboratory
- Subject has persistent severe neutropenia (defined as an absolute neutrophil count
[ANC] <= 500/mm3)
- Subject has creatinine clearance values, calculated according to the formula below,
which are < 60% of normal for age and gender for males: CLcr = [(140 - Age(years)) *
(body weight (kg))] / [72 * (Serum Creatinine (mg/dL))] for females: CLcr = [(140 -
Age(years)) * (body weight(kg)) * 0. 85] / [72 * (Serum Creatinine (mg/dL))]
- Subject has malignancy other than adequately treated basal cell or squamous cell
carcinoma of the skin or carcinoma in situ of the cervix
- Subject has a history of thrombotic episodes (including deep vein thrombosis,
myocardial infarction, cerebrovascular accident, pulmonary embolism) within the last
12 months
- Subject has abnormal protein loss (protein losing enteropathy, nephrotic syndrome)
- Subject has anemia that would preclude phlebotomy for laboratory studies
- Subject has received any blood or blood product other than an IGIV, SC
immunoglobulin, immune serum globulin (ISG) preparation, or albumin within the 6
months prior to enrollment
- Subject has an ongoing history of hypersensitivity or persistent reactions
(urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following IGIV,
SC immunoglobulin, and/or ISG infusions
- Subject has immunoglobulin A (IgA) deficiency and known anti IgA antibodies
- Subject is on preventative (prophylactic) antibiotics and cannot stop antibiotics at
the time of enrollment
- Subject has active infection who started on antibiotic therapy for the treatment of
infection within 7 days prior to screening
- Subject has a bleeding disorder or are on anti-coagulation therapy
- Subject has total protein > 9 g/dL and subjects with myeloma, macroglobulinemia (IgM)
and paraproteinemia
- Subject has a known allergy to hyaluronidase
- If female, subject is pregnant or lactating at the time of study enrollment
- Subject has participated in another clinical study involving an investigational
product (IP) or device within 30 days prior to study enrollment or is scheduled to
participate in another clinical study involving an IP or device during the course of
this study; exception: Baxter Study No. 160601
Locations and Contacts
St. Paul´s Hospital, Pacific Lung Health Centre, Vancouver, British Columbia V6Z 1Y6, Canada
West Coast Clinical Trials, Cypress, California 90360, United States
University of California, Irvine, Irvine, California 92697, United States
Children´s Hospital Los Angeles, Division of Clinical Immunology & Allergy, Los Angeles, California 90027, United States
UCLA Schoold of Medicine / UCLA Medical Center, Dept. of Pediatrics, Los Angeles, California 90095, United States
University of California, San Francisco, California 94143, United States
IMMUNOe International Research Centers, Centennial, Colorado 80112, United States
Allergy Associates of the Palm Beaches, P.A., North Palm Beach, Florida 33408, United States
Emory University, Atlanta, Georgia 30322, United States
Allergy and Asthma Physicians, Hinsdale, Illinois 60521, United States
Allergy Asthma & Immunology Associates, Omaha, Nebraska 68124, United States
Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10461, United States
Dallas Allergy Immunology Research, 7777 Forest Lane, Suite B-332, Dallas, Texas 75230, United States
University of Texas Medical Branch, Galveston, Texas 77555-0561, United States
Additional Information
Starting date: December 2008
Last updated: November 30, 2011
|
